Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P08922
UPID:
ROS1_HUMAN
Alternative names:
Proto-oncogene c-Ros; Proto-oncogene c-Ros-1; Receptor tyrosine kinase c-ros oncogene 1; c-Ros receptor tyrosine kinase
Alternative UPACC:
P08922; Q15368; Q5TDB5
Background:
Proto-oncogene tyrosine-protein kinase ROS, known as c-Ros receptor tyrosine kinase, plays a pivotal role in epithelial cell differentiation and the regionalization of the proximal epididymal epithelium. It activates several signaling pathways, including the PI3 kinase-mTOR pathway, crucial for cell differentiation, proliferation, growth, and survival. It phosphorylates PTPN11, STAT3, VAV3, AKT1, MAPK1, MAPK3, IRS1, and PLCG2, mediating various cellular functions.
Therapeutic significance:
Understanding the role of Proto-oncogene tyrosine-protein kinase ROS could open doors to potential therapeutic strategies.